BiotechTube

XB2001 or Placebo

Phase 1/2Active
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pancreatic Cancer

Conditions

Pancreatic Cancer

Trial Timeline

May 27, 2021 → Jun 10, 2025

NCT ID
NCT04825288

About XB2001 or Placebo

XB2001 or Placebo is a phase 1/2 stage product being developed by XBiotech for Pancreatic Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04825288. Target conditions include Pancreatic Cancer.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT04825288Phase 1/2Active

Competing Products

20 competing products in Pancreatic Cancer

See all competitors
ProductCompanyStageHype Score
Autologous Mesothelin-specific TCR-T Cells + Cyclophosphamide + Fludarabine + BendamustineLonzaPhase 1
30
pemetrexedEli LillyPhase 2
52
mFOLFIRINOX + RamucirumabEli LillyPhase 2
52
[203Pb]Pb-PSV359 + [212Pb]Pb-PSV359Perspective TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
enzastaurin + gemcitabineEli LillyPhase 2
52
Cyclophosphamide + GVAX Pancreas Vaccine (GVAX) + Pembrolizumab + IMC-CS4Eli LillyPhase 1
33
RamucirumabEli LillyPhase 1/2
41
GEMZAR + ALIMTAEli LillyPhase 3
77
CS-1008 (humanized anti-DR5 antibody) + gemcitabineDaiichi SankyoPhase 2
52
exatecan mesylateDaiichi SankyoPhase 2
52
exatecan mesylate + gemcitabine hydrochlorideDaiichi SankyoPhase 3
77
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
AGS-1C4D4 + gemcitabineAstellas PharmaPhase 2
52
erlotinib + gemcitabine + nab-paclitaxelAstellas PharmaPhase 1
33
erlotinib hydrochloride + gemcitabine hydrochlorideAstellas PharmaPhase 1
33
AGS-1C4D4 + GemcitabineAstellas PharmaPhase 2
52
Tarceva (erlotinib HCl, OSI-774)Astellas PharmaPhase 3
77
Enzalutamide + Gemcitabine + Nab-paclitaxelAstellas PharmaPhase 1
33

Other Products from XBiotech

Natrunix with MTX placebo (+folate) + Natrunix placebo with MTX (+folate)Phase 2
44
Natrunix 400 mg + Placebo + Methotrexate (MTX)Phase 2
44
Natrunix + PlaceboPhase 2
44
Natrunix + PlaceboPhase 2
44
514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase IIPhase 1/2
33